12/7/2023 0 Comments Kite pharma fda![]() On 18 October 2017, Yescarta became the first CAR-T therapy approved by the FDA for treating certain types of large B-cell lymphoma, as well as the first CAR-T filed with the European Medicines Agency (EMA) for listing application. Arie Belldegrun, Founder of Kite Pharma, commented, "We are committed to providing advanced tumor cellular immunotherapy to global cancer patients, and Fosun Pharma is our ideal partner in China for promoting Yescarta." ![]() ![]() As the global cell therapy leader, Kite has treated more patients with CAR T-cell therapy than any other company. “Fosun has set up a world class R&D and manufacturing platform in Shanghai through its collaboration with Gilead Science and Kite, and today’s inauguration is testament to Fosun’s continued commitment to bringing the highest quality treatments to Chinese patients.” Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, focused on cell therapy to treat and potentially cure cancer. Guo Guangchang, Chairman of Fosun International. “With CAR-T, we take another major leap in the fight against cancer,” said Mr. Yescarta has the potential to become the first cell therapy product approved for cancer patients in China, which carries great significance and sets standards for commercialization of CAR-T cell therapy. Through Yescarta, Fosun Kite is committed to introducing the world’s cutting-edge CAR-T technology for Chinese cancer patients. Fosun Kite will now accelerate the technology transfer, validation and registration of Kite’s first FDA-approved product, KTE-C19 (trade name “Yescarta"). In December 2017, Fosun Kite established an advanced cell therapy manufacturing facility under the national standards of Good Manufacturing Practices (GMP) and under Kite Pharma’s technology and facility design. On September 30, 2022, KITE-222, an investigational chimeric antigen receptor (CAR) T-cell therapy, was granted orphan drug designation by the U.S. (“Fosun Kite”) inaugurated a manufacturing facility for cancer cell therapy in Zhangjiang, Shanghai.įosun Kite is a joint venture between Fosun Pharma and Kite Pharma based in Shanghai. December 5, 2017, Fosun Kite Biotechnology Co., Ltd.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |